Nichols & Pratt Advisers LLP MA Has $41.11 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Nichols & Pratt Advisers LLP MA reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 477,879 shares of the company’s stock after selling 10,331 shares during the quarter. Novo Nordisk A/S accounts for approximately 2.7% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 15th biggest position. Nichols & Pratt Advisers LLP MA’s holdings in Novo Nordisk A/S were worth $41,107,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $28,000. Center for Financial Planning Inc. grew its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S in the third quarter valued at $42,000. Dunhill Financial LLC boosted its position in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after purchasing an additional 311 shares during the period. Finally, Albion Financial Group UT boosted its position in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $90.68 on Friday. The stock’s 50-day moving average is $84.82 and its 200 day moving average is $106.90. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1-year low of $77.82 and a 1-year high of $148.15. The stock has a market cap of $406.91 billion, a price-to-earnings ratio of 27.56, a P/E/G ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.